Tech Center 1600 • Art Units: 1645 1648 1671 1672
This examiner grants 58% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17473968 | HIGH-THROUGHPUT METHODS TO CHARACTERIZE PHAGE RECEPTORS AND RATIONAL FORMULATION OF PHAGE COCKTAILS | Final Rejection | The Regents of the University of California |
| 17670091 | PRIMER DESIGN AND USE FOR LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) PATHOGEN DETECTION | Non-Final OA | Purdue Research Foundation |
| 17783038 | GENE TRANSFER SYSTEM | Final Rejection | The University of North Carolina at Chapel Hill |
| 18296357 | ANALYSIS OF VIRAL PARTICLES BY DIGITAL ASSAY | Non-Final OA | Bio-Rad Laboratories, Inc. |
| 17996797 | LIPID NANOPILLAR ARRAY-BASED IMMUNOASSAY | Non-Final OA | KOREA INSTITUTE OF MACHINERY & MATERIALS |
| 18567814 | 2019 NOVEL CORONAVIRUS ANTIBODY-CONTAINING PHARMACEUTICAL FORMULATIONS | Non-Final OA | Eli Lilly and Company |
| 16975541 | NOVEL ADENO-ASSOCIATED VIRUS (AAV) VECTORS, AAV VECTORS HAVING REDUCED CAPSID DEAMIDATION AND USES THEREFOR | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17679521 | METHODS AND SYSTEMS FOR PERFORMING A PATIENT-SPECIFIC IMMUNOTHERAPY PROCEDURE WITH CHAIN-OF-CUSTODY AND CHAIN-OF-IDENTITY BIOLOGICAL SAMPLE TRACKING | Final Rejection | Kite Pharma, Inc. |
| 18458108 | EPSTEIN BARR VIRUS VACCINES | Non-Final OA | Fred Hutchinson Cancer Center |
| 18259748 | NEUTRALIZING MONOCLONAL ANTIBODIES AGAINST COVID-19 | Non-Final OA | FRED HUTCHINSON CANCER CENTER |
| 17627854 | HOST-INDEPENDENT EXPRESSION OF BACTERIOPHAGES | Non-Final OA | TECHNISCHE UNIVERSITÄT MÜNCHEN |
| 17534043 | Methods and Systems for the Detection of Microorganisms Using Infectious Agents | Non-Final OA | Laboratory Corporation of America Holdings |
| 17998592 | STABILIZED CORONAVIRUS SPIKE PROTEIN FUSION PROTEINS | Non-Final OA | Janssen Pharmaceuticals, Inc. |
| 16327473 | 2D ORGANOID FOR INFECTION AND CULTURE OF HUMAN DIARRHEA VIRUS, AND USE OF SAID 2D ORGANOID | Non-Final OA | Keio University |
| 17048297 | IMMUNO-ONCOLYTIC MODIFIED VACCINIA TIAN TAN VIRUS AND METHODS OF TREATING CANCER | Final Rejection | The University of Hong Kong |
| 18560338 | METHODS AND COMPOSITION FOR INDUCING AN IMMUNE RESPONSE BY A RECOMBINNAT VACCINIA VIRUS | Non-Final OA | UNIVERSITY OF ROCHESTER |
| 18250685 | REPORTER MYCOBACTERIOPHAGE, ASSAYS AND METHODS COMPRISING THE REPORTER MYCOBACTERIOPHAGE | Non-Final OA | Albert Einstein College of Medicine |
| 18094117 | INFECTIOUS RECOMBINANT VESICULAR STOMATITIS VIRUS (RVSV) BEARING THE SPIKE GLYCOPROTEIN S OF SARS-COV-2 AND USES THEREOF | Non-Final OA | Albert Einstein College of Medicine |
| 17603302 | MODIFIED AAV VECTORS THAT DAMPEN THE HUMORAL IMMUNE RESPONSE | Non-Final OA | University of Florida Research Foundation, Incorporated |
| 18564987 | METHODS AND COMPOSITIONS FOR TRANSDUCTION OF NK CELLS | Non-Final OA | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. |
| 18008391 | IDENTIFICATION OF LOW-DENSITY INFLAMMATORY NEUTROPHILS IN SEVERE COVID-19 PATIENTS | Non-Final OA | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. |
| 17913575 | METHODS AND COMPOSITIONS FOR DETECTING VIRUSES | Non-Final OA | University of Louisville Research Foundation, Inc. |
| 17905040 | METHOD FOR PRODUCING INACTIVATED INFLUENZA VACCINE AND VACCINE COMPOSITION THEREOF | Final Rejection | DENKA COMPANY LIMITED |
| 17262098 | ANTIGEN PURIFICATION METHOD | Final Rejection | GLAXOSMITHKLINE BIOLOGICALS SA |
| 18567179 | RECOMBINANT VSV FOR THE TREATMENT OF BLADDER CANCER | Non-Final OA | SOCIETE DE COMMERCIALISATION DES PRODUITS DE LA RECHERCHE APPLIQUEE SOCPRA SCIENCES SANTE ET HUMAI |
| 18473956 | COMPOSITIONS FOR CORONAVIRUS DETECTION AND METHODS OF MAKING AND USING THEROF | Non-Final OA | THE HOSPITAL AUTHORITY |
| 18280150 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | Non-Final OA | ROCKETVAX AG |
| 17909145 | FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES | Non-Final OA | ROCKETVAX AG |
| 18278208 | POLYPEPTIDES MIMICKING MPER AND V3-LOOP HIV-1 ENV GLYCOPROTEIN EPITOPES | Non-Final OA | NEXIUM, S.R.O. |
| 18278191 | AN ISOLATED POLYPEPTIDE | Non-Final OA | UNIVERSITY OF ULSTER |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy